SS
ENTA icon

Sunbelt Securities’s Enanta Pharmaceuticals ENTA Stock Holding History

Sunbelt Securities’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$796 Hold
63
– – ﹤0.01% 2159
2025
Q4 		$994 Hold
63
– – ﹤0.01% 2056
2025
Q3 		$754 Buy
+63
New +$503 ﹤0.01% 2124

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Sunbelt Securities's ENTA Position: Q1 2026 in Review

Sunbelt Securities held its Enanta Pharmaceuticals (ENTA) position steady in Q1 2026 at 63 shares worth $796. The position accounts for ﹤0.01% of the portfolio, ranked #2159.

Sunbelt Securities first reported a position in ENTA in Q3 2025 and has held it in 3 quarters since. The position peaked at $994 in Q4 2025. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • Sunbelt Securities held 63 shares of Enanta Pharmaceuticals worth $796 as of Q1 2026.
  • Sunbelt Securities left its Enanta Pharmaceuticals share count unchanged in Q1 2026.
  • Enanta Pharmaceuticals made up ﹤0.01% of Sunbelt Securities's portfolio in Q1 2026, its #2159 holding.
  • Sunbelt Securities first reported a position in Enanta Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Sunbelt Securities's Enanta Pharmaceuticals position peaked at $994 in Q4 2025.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Sunbelt Securities's 13F filing for Q1 2026, filed 18 May 2026.